INDOAMIN vs STYRENIX: Stock Comparison
STYRENIX PERFORMANCE is the larger company by market capitalisation. INDOAMIN shows a lower P/E, a higher ROE and faster revenue growth, while STYRENIX PERFORMANCE shows a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
INDOAMIN leads 10; STYRENIX leads 3 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | INDOAMIN | STYRENIX |
|---|---|---|
| Sector | Chemicals | Chemicals |
| Industry | Specialty Chemicals | Specialty Chemicals |
Price
| Metric | INDOAMIN | STYRENIX |
|---|---|---|
| Live Price | ₹137.95 | ₹2,113.1 |
| Day Change | -1.75% | -1.39% |
| Volume | 1.39 L | 34,221 |
| 52-Week High | ₹149 | ₹2,653.8 |
| 52-Week Low | ₹81.9 | ₹1,780 |
| Distance from 52W High | -7.42% | -20.37% |
Valuation
| Metric | INDOAMIN | STYRENIX |
|---|---|---|
| Market Cap | ₹928 Cr | ₹3,708 Cr |
| P/E Ratio | 11.47x | 13.59x |
| P/B Ratio | 2.37x | 2.71x |
| EPS | ₹4.22 | ₹78.09 |
| Book Value | ₹54.25 | ₹776.95 |
| Dividend Yield | 0.39% | 2.18% |
Growth
| Metric | INDOAMIN | STYRENIX |
|---|---|---|
| Revenue Growth (TTM YoY) | 11.3% | -12.1% |
| EPS Growth (TTM YoY) | 76% | 30.9% |
| Qtr Sales Growth | -1.96% | -24.02% |
| Qtr Profit Growth | -0.48% | -0.71% |
Profitability & Leverage
| Metric | INDOAMIN | STYRENIX |
|---|---|---|
| ROE | 20.14% | 13.38% |
| ROCE | 13.9% | 12.38% |
| Net Margin | 6.84% | 5.42% |
| Operating Margin | 11.2% | 7.06% |
| Debt to Equity | 0.79x | 0.23x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | INDOAMIN | STYRENIX |
|---|---|---|
| Promoter Holding | 58.42% | 46.24% |
| FII Holding | 0.08%▲ 0.06 pp | 0.86%▼ 0.09 pp |
| DII Holding | 0% | 17.44%▲ 0.11 pp |
| Public Holding | 41.5%▼ 0.06 pp | 35.46%▼ 0.02 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: INDOAMIN and STYRENIX PERFORMANCE.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.